<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0102233199
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2014
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        GLYPRESSIN 0.1 mg/ml solution for injection
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TERLIPRESSIN DIACETATE PENTAHYDRATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        8
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Ampoule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        625.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ZENTIVA K.S." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ZENTIVA K.S.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 612]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Abdulrehman Algosaibi G.T.C.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            FERRING
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        H01BA04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>GLYPRESSIN&reg; 0.1 mg/ml solution for injection contains terlipressin, which is a synthetic pituitary hormone. (This hormone is usually produced by the pituitary gland found in the brain).<br />It will be given to you by injection into a vein.</p><p><br />GLYPRESSIN&reg; 0.1 mg/ml solution for injection is used for treatment of bleeding from varices in the food pipe (bleeding oesophageal varices).</p><p><br />Esophageal varices are enlarged blood vessels, which may be formed in the food pipe during hepatic diseases. They may burst and bleed and thus cause a life-threatening state.</p><p><br />After injection into blood circulation, the active ingredient terlipressin is changed into lysine-vasopressin. This happens at the walls of the blood vessels, which means narrowing of the blood vessels, which leads to reduction of blood flow and reduction of bleeding.</p><p><br />The administration of terlipressin is for emergency treatment in cases of acute bleeding from esophageal varices until endoscopic therapy is available (therapeutic measures done at and by inspection of the food pipe). Afterwards, administration of terlipressin for the treatment of bleeding from esophageal varices is usually an adjuvant therapy to the endoscopic stopping of bleeding. Terlipressin can also be used for reducing early secondary bleeding.</p><p><br />GLYPRESSIN&reg; 0.1 mg/ml solution for injection is also used as an emergency treatment of type 1 hepatorenal syndrome (rapidly progressive renal failure) in patients with liver cirrhosis and ascites.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use GLYPRESSIN&reg; 0.1 mg/ml solution for injection</strong><br />- if you are allergic to terlipressin or any of the other ingredients of this medicine (listed in section 6);<br />- if you are pregnant;<br />- In case of septic shock combined with low heart function (a septic shock is a severe disease, which appears, if a severe infection causes low blood pressure and reduced blood flow).<br />- if you suffer from ischemic cardiovascular disease (a condition that affects the supply of blood to the heart and other organs ) as this condition may be aggravated.<br /><strong>Warnings and precautions</strong><br />This medicinal product is administered to you if you have bleeding in your food pipe, which is in most cases life-threatening. It is therefore used under continuous monitoring of your blood pressure, heart rate and fluid balance. Your doctor should give you the injection intravenously to avoid tissue damage through dying cells (necrosis) at injection site.<br />If you are able to then tell your doctor if you suffer from the conditions shown below.<br />Please inform your doctor, if you have any of the conditions below:<br />- a severe infection, known as septic shock;<br />- bronchial asthma or other conditions that affect your breathing;<br />- uncontrolled high blood pressure, insufficient blood circulation of the coronary vessels (e.g. angina), coronary insufficiency, previous heart attack (myocardial infarction) or advanced arterial calcification (arteriosclerosis);<br />- seizures (convulsions);<br />- irregular heartbeats (cardiac arrhythmias) or a history of QT interval prolongation (disturbance of heart rhythm);<br />- heart diseases;<br />- poor blood circulation to your brain (e.g. you have had a stroke) or to your limbs (peripheral vascular dis-ease);<br />- impaired kidney function (renal insufficiency);<br />- if you suffer from a disturbances in the level of salt (electrolytes) in your blood;<br />- if you suffer from a reduced amount of fluid in your circulation or have already lost a large amount of blood;<br />- If you are over the age of 70 years.<br /><strong>Children and adolescents</strong><br />Because of limited experience, this medicine should not be used in children and adolescents.<br /><strong>Elderly</strong><br />The dose for elderly is defined by the doctor.<br /><strong>Other medicines and GLYPRESSIN&reg; 0.1 mg/ml solution for injection</strong><br />Tell your doctor or pharmacist if you are taking/using, have recently taken/used or might take/use any other medicines.<br />Please inform your doctor immediately if you take any of the following medicines:<br />&bull; drugs that have an effect on your heart rate (e.g. beta-blockers, propofol or sufentanil);<br />&bull; drugs that can trigger irregular beating of the heart (arrhythmia) such as the following:<br />- anti-arryhthmic drugs known as Class IA (quinidine, procainamide, disopyramide) and Class III (amiodarone, sotalol, ibutilide, dofetilide);<br />- erythromycin (an antibiotic);<br />- antihistamines (mainly used to treat allergies but also found in certain cough and cold remedies)<br />- tricyclic antidepressants used to treat depression;<br />- Medicines that may alter the level of salt or electrolytes in your blood, particularly diuretics (water tablets used to treat high blood pressure and heart failure).</p><p><strong>Pregnancy and breast-feeding</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.<br /><strong>Pregnancy</strong><br />GLYPRESSIN&reg; 0.1 mg/ml solution for injection must not be used during pregnancy.<br /><strong>Breast-feeding</strong><br />It is not known if GLYPRESSIN&reg; 0.1 mg/ml solution for injection is present in breast milk, therefore the possible effects on your baby are unknown. You should discuss the potential risk to your baby with your doctor.<br />Ask your doctor or pharmacist for advice before taking any medicine.<br /><strong>Driving and using machines</strong><br />No studies on the effects on ability to drive and use machines have been performed.</p><p>GLYPRESSIN&reg; 0.1mg/ml solution for injection contains sodium</p><p>8,5 ml of GLYPRESSIN&reg; 0.1 mg/ml solution for injection contains 1,34 mmol (30,71 mg) sodium. Consider this, if you are on a low-sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>This medicine will always be given to you by a doctor into your vein. The doctor will decide the most appropriate dose for you and your heart and blood circulation will be continuously monitored during the injection. Please ask your doctor for further information regarding its use.</p><p><br /><em>The recommended dose is:</em><br /><u>Bleeding from varices in the food pipe (bleeding oesophageal varices):</u><br />Unless otherwise prescribed, initially 0.85 to 1.7 mg terlipressin is slowly administered intravenously in adults. The maintenance dose is 0.85 mg terlipressin each after 4-6 hours.<br />The maximum daily dosage of terlipressin is 120-150 &mu;g/kg body weight. For an adult person of 70 kg body weight, this corresponds to a dosage of 8 to 9 vials per day, to be administered in 4-hour intervals. The duration of treatment is 2 &ndash; 3 days, depending on the course of your condition.<br /><u>Hepatorenal syndrome</u><br />Terlipressin is usually started at a dose of 0.85 mg of terlipressin every 4 to 6 hours. If the reduction of serum creatinine is less than 25% after 3 days of treatment your doctor can increase the dose to a maximum of 1.7 mg terlipressin every 4 hours. Treatment is maintained until normal kidney function is restored to a maximum of 14 days.<br /><u>Method of administration</u><br />GLYPRESSIN&reg; 0.1 mg/ml solution for injection is administered intravenously (directly into blood circulation).</p><p><br /><strong>Use in the elderly</strong><br />If you are over 70 years of age speak with your doctor before you receive GLYPRESSIN&reg; 0.1 mg/ml solution for injection.<br /><strong>Use in patients with kidney problems</strong><br />GLYPRESSIN&reg; 0.1 mg/ml solution for injection should be used with caution in patients with long standing kidney failure.<br /><strong>Use in patients with liver problems</strong><br />No dose adjustment is required in patients with liver failure.<br /><strong>Use in children and adolescents</strong><br />GLYPRESSIN&reg; 0.1 mg/ml solution for injection is not recommended for use in children and adolescents due to insufficient experience.<br /><strong>If you use more GLYPRESSIN&reg; 0.1 mg/ml solution for injection than you should</strong><br />As this medicine is given by a healthcare professional, then it is unlikely you will be given more than the recommended dose. If you are given too much then you may have a rapid increase in your blood pressure (this will be noticed during the continuous monitoring), especially if you already suffer with high blood pressure. If this happens then you will be given another medicine called an alpha blocker (e.g. clonidine) to control your blood pressure.<br />If you experience lightheadedness, dizziness, or feeling faint, tell your doctor because these could be signs of a low heart rate. This can be treated with another medicine called atropine.<br /><strong>If you forget to use GLYPRESSIN&reg; 0.1 mg/ml solution for injection</strong><br />You will be given GLYPRESSIN&reg; 0.1 mg/ml solution for injection in hospital under the supervision of a doctor.</p><p><strong>If you stop using GLYPRESSIN&reg; 0.1 mg/ml solution for injection</strong></p><p>Your doctor will advise when it is time to stop receiving this medicine.<br />If you have any further questions on the use of this medicine, ask your doctor, nurse, or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Common </strong>(affects 1 of 10&nbsp;treated patients)<br />&bull; Sodium deficiency in blood (hyponatraemia).<br />&bull; Headache.<br />&bull; Too slow heart rate (bradycardia).<br />&bull; Disordered action of the heart (arrhythmia).<br />&bull; Signs of insufficient blood circulation through coronary vessels in ECG/EKG.<br />&bull; Peripheral narrowing of vessels (arms and legs).<br />&bull; Peripheral reduced blood circulation (arms and legs)<br />&bull; High blood pressure (hypertension).<br />&bull; Pallor of skin.<br />&bull; Low blood pressure (hypotension).<br />&bull; Cramp-like stomach pain.<br />&bull; Nausea.<br />&bull; Diarrhea.<br />&bull; Cramp-like abdominal pain (in women).<br /><strong>Uncommon </strong>(affects 1 of 100&nbsp;treated patients):<br />&bull; Causing of seizure disorders.<br />&bull; Racing heart (tachycardia).<br />&bull; Special disorders of heart rate (atrial fibrillation, ventricular extrasystoles).<br />&bull; Pain in the chest caused by insufficient blood circulation of coronary vessels (angina pectoris).<br />&bull; Heart attack (myocardial infarction).<br />&bull; Overload of liquid with discharge of liquid out of small lung vessels (pulmonary capillaries) into lung tissue.<br />&bull; Special disorders of heart rhythm (torsades de pointes).<br />&bull; Weakness of the heart (cardiac insufficiency).<br />&bull; Reduced blood circulation of stomach arteries (intestinal ischaemia).<br />&bull; Slowdown of blood flow because of high oxygen extraction through organs and bluish colouration of the skin and lips (peripheral cyanosis).<br />&bull; Hot flushes.<br />&bull; Difficulty in breathing.<br />&bull; Painful breathing.<br />&bull; Pain in the chest (thoracic pain).<br />&bull; Cramps of bronchial musculature (bronchial spasms).<br />&bull; Respiratory insufficiency.<br />&bull; Cessation of breathing.<br />&bull; Vomiting.<br />&bull; Inflammation of lymphatic vessels (lymphangitis) seen as fine red streaks under your skin extending from the affected area to the armpit or groin and by fever, chills, headache, and muscle pain.<br />&bull; Tissue damage caused by dying of cells (necrosis) of the skin.<br />&bull; Increased tension of the uterus (uterine hypertonus).<br />&bull; Decreased blood flow in the uterus<br />&bull; Tissue damage caused by dying of cells (necrosis) at injection site.<br /><strong>Rare </strong>(affects 1 of 1,000 treated patients): Difficulty in breathing (dyspnoea).<br /><strong>Very rare</strong> (may affect&nbsp;affect up to 1 of 10,000 treated patients): Apoplexy.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>Do not use the medicinal product after the expiry date, which is stated on the outer carton/container. The expiry date refers to the last day of that month.<br />Store in a refrigerator (2&deg;C &ndash; 8&deg;C). Keep the ampoules in the outer carton in order to protect from light.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><u>The active ingredient is:</u> 1 ampoule with 8.5 ml of solution contains terlipressin acetate equivalent to 0.1 mg terlipressin/ml.<br /><u>The other ingredients are:</u> sodium chloride, acetic acid 99 %, sodium acetate trihydrate, water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                GLYPRESSIN® 0.1 mg/ml solution for injection is a clear, colourless solution.
GLYPRESSIN® 0.1 mg/ml solution for injection is available in packages of 5 ampoules each containing 8.5 ml of solution.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder: </strong>FERRING GmbH, Wittland 11, D-24109 Kiel, Germany</p><p><strong>Manufacturer</strong>: Zentiva k.s., U Kabelovny 130, 102 37, Prague, Czech Republic</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                January 2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي عقار جليبريسين&nbsp;0.1&nbsp;ملغم/ مل محلول للحقن&nbsp;على تيرليبريسين، وهو أحد هرمونات الغدة النخامية التَّخليقية. (يُنتج هذا الهرمون عادةً عن طريق&nbsp;الغدة النخامية الموجودة في المخ).&nbsp;سيعطى لك عن طريق الحقن في الوريد</p><p>بستخدم عقار جليبريسين&nbsp;0.1 ملغم/ مل محلول للحقن&nbsp;لعلاج النزيف النَّاجم عن الدَّوالي التي تصيب المريء (دوالي المريء النزفية).</p><p>دوالي المريء هي عبارة عن توسُّع في الأوعية الدَّموية، والتي قد تتشكل في المريء أثناء الإصابة بأمراض الكبد. قد تنفجر الدَّوالي وتنزف، وبالتَّالي تتسبب في<br />حدوث حالة ُ مهدد للحياة.</p><p>بعد الحقن في الدَّورة الدَّموية، تتغيَّر المادة الفعَّالة تيرليبريسين إلى لايسين - فازوبريسين. يحدث هذا على جدران الأوعية الدَّموية،وهو ما يعني حدوث تضيُّق بالأوعية الدَّموية، مما يُؤدي إلى انخفاض تدفُّق الدَّم وبالتَّالي تقليل النزيف.</p><p>يتم إعطاء تيرليبريسين لعلاج حالات الطَّوارئ في حالات النزيف الحاد النَّاجم عن دوالي المريء حتى يتوفر العلاج بالتَّنظير الدَّاخلي ( تجرى التَّدابير العلاجية عند فحص المريء). بعد ذلك، يتم إعطاء تيرليبريسين لعلاج النزيف النَّاجم عن دوالي المريء عادةً كعلاج ُ مساعد لإيقاف النزيف بالتَّنظير الدَّاخلي. ُ يمكن ايضا أن يستخدم تيرليبريسين لتقليل النزيف الثانوي المبكر.</p><p>يستخدم جليبريسين 0.1 ملغم/ مل محلول للحَقْن أيضا كعلاج طارىء&nbsp;لمتلازمة الكبد من النوع الأول (الفشل الكلوي التدريجي السريع)في المرضى&nbsp;الذين يعانون من تليف الكبد والاستسقاء</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تستخدم عقار جليبريسين&nbsp;0.1 ملغم/ مل محلول للحقن في الحالات الآتية:</strong></p><p>- إذا كنت تعاني من حساسية تجاه تيرليبريسين أو تجاه أي مكون من المكونات الأخرى بهذا الدَّواء (المدرجة في قسم6)</p><p>- إذا كنت حاملا؛<br />- في حال حدوث صدمة إنتانية مصاحبة لقصور بوظائف القلب (الصدمة الإنتانية هي مرض شديد، يظهر إذا تسببت العدوى الشديدة في انخفاض ضغط الدَّم&nbsp;وانخفاض تدفُّق الدَّم).&nbsp;</p><p>- اذا كنت تعاني من أمراض القلب والأوعية الدموية الإقفارية (وهي حالة تؤثر على وصول الدم إلى القلب والأعضاء الأخرى) لأن هذه الحالة قد تتفاقم.</p><p><strong>تحذيرات واحتياطات</strong></p><p>تحدَّث إلى طبيبك أو الصيدلي الخاص بك قبل استخدام عقار جليبريسين&nbsp;0.1 ملغم/ مل محلول للحقن.</p><p>يتم إعطاؤك هذا المنتج الدَّوائي إذا كنت ُ مصابًا بنزيف في المريء والذي يكون في غالبية الحالات ُ مهددا للحياة. لذا، يُستجدم هذا الدَّواء في ظل مراقبة مستمرة&nbsp;لضغط الدَّم و ُ معدَّل ضربات القلب وتوازن السوائل لديك. يجب أن يُعطيك طبيبك الحقن عن طريق الوريد؛ لتجنُّب حدوث تلف بالأنسجة من خلال الخلايا الميتة (النخر) في موضع الحقن.</p><p>إذا كنت قادرًا بعد ذلك فأخبر طبيبك إذا عانيت من الحالات الموضَّحة أدناه:</p><p>يرجى إبلاغ طبيبك إذا كنت تعاني من الحالات الآتية:</p><p>- عدوى شديدة، تُعرَف باسم الصدمة الإنتانية؛</p><p>- ربو ُ شعبي أو حالات أخرى تُؤثر على تنفسك؛</p><p>- ارتفاع ضغط الدَّم غير المنضبط، قصور في الدَّورة الدَّموية بالأوعية لتَّاجية (على سبيل المثال: الذبحة الصدرية)، قصور في الشريان التَّاجي، نوبة قلبية سابقة (احتشاء عضلة القلب) أو تكلس شرياني متقدم (تصلُّب الشرايين)؛</p><p>- نوبات صرع (تشنجات)؛</p><p>- عدم انتظام ضربات القلب (اضطرابات النَّظم القلبي) أو تاريخ سابق من إطالة فترة&nbsp;&quot;QT&quot; (اضطراب في النظم القلبي)؛</p><p>-أمراض القلب؛&nbsp;</p><p>ضعف الدَّورة الدَّموية إلى المخ لديك (على سبيل المثال: إذا كنت قد أُصبت بسكتة دماغية) أو إلى الأطراف (مرض وعائي طرفي)؛</p><p>- قصور بوظائف الكُلى؛</p><p>- إذا كنت تُعاني من اضطرابات في مستوى الملح (الكهرليات) لديك في الدَّم؛</p><p>- إذا كنت تُعاني من انخفاض كمية السوائل في دورتك الدَّموية أو فقدت بالفعل كمية كبيرة من الدَّم؛</p><p>- إذا كان سنك يزيد عن ٧٠ عاما.</p><p><strong>الأطفال والمراهقون</strong></p><p>يجب أَلَّا يستخدم هذا العقار للأطفال والمراهقين، نظرًا إلى وجود خبرة محدودة.</p><p><strong>المرضى من كبار السن</strong></p><p>يحدد الطبيب الجرعة للمرضى من كبار السن.</p><p>يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك إذا كنت تتناول/ تستخدم أو تناولت/ استخدمت مؤخرًا أو قد تتناول/ تستخدم أيَّة أدوية أخرى.</p><p>أخبر طبيبك فورًا، إذا كنت تتناول أياً&nbsp;من الأدوية التَّالية:</p><p>&bull; العقاقير ذات التَّأثير على معدل ضربات القلب لديك (على سبيل المثال: حاصرات بيتا أو بروبوفول أو سوفينتانيل)؛</p><p>&bull; العقاقير التي تحفز عدم انتظام ضربات القلب (اضطرابات النَّظم القلبي) مثل ما يلي:</p><p>- مضادات اضطراب النَّظم القلبي والتي تُعرَف بكونها من الفئة &quot; 1أ&quot; (كينيدين، بروكايناميد، ديسوبيراميد) والفئة &quot; ٣&quot; (أميودارون، سوتالول، إبيوتيليد، دوفتيليد)؛<br />- إريثروميسين (مضاد حيوي)؛</p><p>- مضادات الهيستامين (تُستخدم بشكل أساسي لعلاج حالات الحساسية ولكنها أيضا توجد في بعض علاجات السُّعال والبرد)؛<br />- مضادات الاكتئاب ثلاثية الحلقات التي تُستخدم في علاج الاكتئاب؛</p><p>- الأدوية التي قد تغير مستوى الملح أو الكهرليات لديك في الدَّم، لا سيَّما ُ مدرات البول (أقراص&nbsp;الماء التي تستخدم لعلاج ارتفاع ضغط الدَّم وفشل القلب).</p><p><strong>الحمل والرضاعة الطبيعية</strong></p><p>إذا كنت حاملا أو مرضعه، أو تعتقدين أنك حامل أو تخططين لذلك، فاستشيري طبيبك أو الصيدلي الخاص بك قبل استخدام هذا الدَّواء.</p><p><strong>الحمل</strong><br />يجب عدم استخدام عقار جليبريسين&nbsp;0.1&nbsp;ملغم/ مل محلول للحقن أثناء الحمل.</p><p><strong>الرَّضاعة الطبيعية</strong></p><p>من غير المعروف ما إذا كان عقار جليبريسين 0.1 ملغم/ مل&nbsp;محلول للحقن يوجد في لبن الأم أم لا، وبالتَّالي فإنَّ التأثيرات المحُتملة على طفلك غير معروفة. يجب&nbsp;</p><p>عليك مناقشة اﻟﻤﺨاطر المحُتمل تعرُّض طفلك لها مع طبيبك.</p><p>استشيري طبيبك أو الصيدلي الخاص بك قبل تناول أي دواء.</p><p><strong>القيادة واستخدام الآلات</strong></p><p>لم يتم إجراء أيَّة دراسات بشأن التَّأثيرات على القدرة على القيادة واستخدام الآلات.</p><p><strong>يحتوي عقار جليبريسين&nbsp;٠٫١&nbsp;ملغم/ مل محلول للحقن على الصوديوم</strong></p><p>يحتوي كل ٨٫٥ مل من عقار جليبريسين&nbsp;&nbsp;0.1 ملغم/ مل محلول للحقن&nbsp;على 1.34مللي مول ( 30.71 ملغم) صوديوم. ضع ذلك في اعتبارك، إذا كنت تتبع نظاما&nbsp;غذائيا&nbsp;منخفض الصوديوم.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>سيتولى الطبيب دائماً&nbsp; إعطاءك هذا الدَّواء في الوريد. سيقرر الطبيب الجرعة الأنسب بالنسبة لك وستتم مراقبة قلبك ودورتك الدَّموية باستمرار أثناء الحقن.<br />رجاء اطلب من طبيبك مزيدا من المعلومات بشأن استخدام العقار.<br />الجرعة الموصى بها هي:</p><p><em>نزيف من دوالي في أنبوب الغذاء (دوالي المريء النزيف):</em><br />ما لم يُوصَف خلا ذلك، في البداية من يتم إعطاء 0،85 إلى 1،7 ملغم من تيرليبريسين ببطء عن طريق الوريد في البالغين. جرعة الصيانة هي<br />0.85 ملغم من تيرليبريسين بعد 4 - 6 ساعات.<br />الحد الأقصى للجرعة اليومية من تيرليبريسين هو 120 - 150 ميكروغرام / كيلوغرام من وزن الجسم. بالنسبة لشخص بالغ&nbsp;يبلغ&nbsp;وزنه 70 كغم،<br />يتوافق هذا مع&nbsp;جرعة من 8 إلى 9 قارورة في اليوم، على أن تعطى كل 4 ساعات. مدة العلاج من 2 إلى 3 أيام، حسب فترة حالتك.<br /><em>متلازمة الكبد</em><br />عادة ما يبدأ تيرليبريسين بجرعة 0.85 مل من تيرليبريسين كل 4 إلى 6 ساعات. إذا كان النقص في نسبة الكرياتينين في الدم أقل من 25 ٪ بعد&nbsp;3 أيام من العلاج، يمكن لطبيبك زيادة الجرعة&nbsp;إلى حد أقصى قدره 1.7 ملغم من تيرليبريسين كل 4 ساعات. تتم المحافظة&nbsp;على العلاج حتى تتم<br />استعادة وظائف الكلى الطبيعية لمدة أقصاها 14 يوما.</p><p>طريقة الاعطاء<br />يُستَخدَم عقار جليبريسين 0.1 ملغم/ مل محلول للحَقْن عن طريق الوريد (في الدورة الدموية مباشرة).</p><p><strong>الاستخدام في كبار السن</strong></p><p>إذا كان سنك يزيد عن ٧٠ عاما، فتحدَّث مع طبيبك قبل تلقي عقار جليبريسين 0.1 ملغم/ مل محلول للحقن.</p><p><strong>الاستخدام في المرضى المصابين بمشاكل في الكُلى</strong></p><p>يجب استخدام عقار جليبريسين&nbsp;0.1&nbsp;ملغم/ مل&nbsp;محلول للحقن بحذر في المرضى المصابين بفشل كُلوي منذ فترة طويلة.</p><p><strong>الاستخدام في المرضى المصابين بمشاكل في الكبد</strong></p><p>لا يستلزم الأمر تعديل الجرعة في المرضى المصابين بفشل الكبد.</p><p><strong>الاستخدام في الأطفال والمراهقين</strong></p><p>لا يوصى باستخدام عقار جليبريسين&nbsp;0.1 ملغم/ مل محلول للحقن في الأطفال والمراهقين لعدم وجود خبرة كافية.&nbsp;</p><p><strong>إذا استخدمت كمية أكثر مما يجب من عقار جليبريسين&nbsp;</strong>0.1<strong> ملغم/ مل محلول للحقن</strong><br />نظرًا إلى أنَّ هذا الدَّواء يعطيه أحد أخصائيي الرعاية الصحية، فمن غير المحُتمل أن يتم إعطاؤك أكثر من الجرعة الموصى بها. إذا تم إعطاؤك كمية أكثر مما يجب فقد<br />تتعرَّض لزيادة سريعة في ضغط الدَّم (سيلاحظ&nbsp;ذلك أثناء إجراء المراقبة المستمرة)، لا سيَّما إذا كنت تُعاني بالأساس من ارتفاع ضغط الدَّم. إذا حدث ذلك، فسيتم<br />إعطاؤك دواء آخر يُسمى حاصر ألفا (على سبيل المثال: كلونيدين) للتَّحكم في ضغط الدَّم لديك.</p><p>إذا شعرت بدوار بالرَّأس أو دوخة أو شعرت بإغماء، فأخبر طبيبك؛<br />لأنَّ هذه قد تكون علامات على تعرُّضك لانخفاض ُ معدَّل ضربات القلب.&nbsp;يمكن علاج ذلك باستخدام دواء آخر يُسمى أتروبين.</p><p><strong>إذا أغفلت استخدام عقار جليبريسين 0.1 ملغم/ مل محلول للحَقْن</strong></p><p>سيتم إعطاؤك عقار جليبريسين 0.1 ملغم/ مل محلول للحَقْن في المستشفى تحت إشراف الطبيب.</p><p><strong>إذا توقفت عن استخدام عقار جليبريسين 0.1 ملغم/ مل محلول للحَقْن</strong></p><p>سينصحك طبيبك بموعد التوقف عن تلقي هذا الدواء.<br />إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدواء، فاستشر طبيبك أو الممرضة أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثله مثل كافة الأدوية، قد يسبب هذا الدَّواء آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p><strong>شائعة:</strong> (تُؤثر على مريض من كل 10 مرضى معالجين):</p><ul><li>نقص الصوديوم بالدَّم؛</li><li>صداع؛</li><li>بطء شديد بمُعدَّل ضربات القلب؛</li><li>اضطراب عمل القلب (اضطرابات النَّظم القلبي)؛</li><li>ظهور علامات الإصابة بقصور الدَّورة الدَّموية خلال الأوعية التَّاجية في رسم القلب الكهربائي؛</li><li>تضيُّق الأوعية الدَّموية الطرفية (الذراعين والساقين)؛</li><li>قصور الدَّورة الدَّموية الطرفية (الذراعين والساقين)؛</li><li>ارتفاع ضغط الدَّم؛</li><li>شحوب الجلد؛</li><li>انخفاض ضغط الدَّم؛</li><li>ألم في المعدة يشبه التَّقلص؛</li><li>غثيان؛</li><li>إسهال؛</li><li>ألم في البطن يشبه التَّقلص (في السيدات).</li></ul><p><strong>غير شائعة</strong> (تؤثر على أقل على مريض من كل100 مريض ُ معالج):</p><ul><li>التَّسبب في حدوث اضطرابات تشنجية؛</li><li>تسارع ضربات القلْب؛</li><li>اضطرابات خاصة بمُعدَّل ضربات القلب (رجفان أذيني، انْقبا َ ضات بطينية خارِجة)؛</li><li>ألم في الصدر ناجم عن قصور الدَّورة الدَّموية بالأوعية التَّاجية (ذبحة صدرية)؛</li><li>نوبة قلبية (احتشاء عضلة القلب)؛</li><li>فرط التَّحميل بالسوائل مع إفراز سوائل من الأوعية الدَّقيقة بالرئة (شعيرات دموية رئوية) في نسيج الرئة؛</li><li>اضطرابات خاصة بالنَّظم القلبي (التفاف النقاط [إحدى العلامات برسم القلب])؛</li><li>ضعف القلب (قصور بوظائف القلب)؛</li><li>قصور الدَّورة الدَّموية بشرايين المعدة (إقْفار معوي)؛</li><li>تباطؤ تدفُّق الدَّم بسبب ارتفاع نسبة ما تستخلصه الأعضاء من الأكسجين وتغيُّر لون الجلد والشفتين إلى لون مائل إلى الأزرق (زُرقة طرفية)؛</li><li>هبات ساخنة؛</li><li>صعوبة في التَّنفس؛</li><li>ألم عند التنفس؛</li><li>ألم في الصدر؛</li><li>تقلُّصات في عضلات الشعب الهوائية (تشنُّجاتُ شعبية)؛</li><li>قصور وظائف الجهاز التَّنفسي؛</li><li>توقف التَّنفس؛</li><li>قيء؛</li><li>التهاب الأوعية الليمفاوية على هيئة خطوط حمراء رقيقة تحت الجلد تمتد من المنطقة المصابة إلى الإبط أو الأربية ويصحبه ُ حمى وقشعريرة وصداع وألم عضلي؛</li><li>تلف بالأنسجة ناجم عن موت الخلايا (النخر) بالجلد؛</li><li>زيادة توتر الرَّحم (فرط توتر الرحم)؛</li><li>انخفاض تدفُّق الدَّم في الرحم؛</li><li>تلف بالأنسجة ناجم عن موت الخلايا (النخر) في موضع الحقن<br /><strong>نادرة </strong>(تؤثر على أقل على مريض من كل1000 مريض ُ معالج): صعوبة في التَّنفس (ضيق التَّنفس).<br /><strong>نادرة&nbsp;جدا</strong>&nbsp;(تؤثر على أقل على مريض من كل10000 مريض ُ معالج): سكتة دماغية.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ بعيدا عن متناول ورؤية الأطفال.</p><p>لا يستخدم هذا المنتج الدَّوائي بعد انتهاء تاريخ الصلاحية المدون على العبوة/ العبوة الكرتونية الخارجية. يُشير تاريخ انتهاء&nbsp;الصلاحية إلى اليوم الأخير من ذلك الشهر. يحفظ في الثلاجة (عند 2 - 8&nbsp;درجة مئوية).&nbsp;احتفظ بالأمبولات داخل العبوة الكرتونية الخارجية لحمايتها من الضوء.</p><p>لا تتخلص من الأدوية عن طريق إلقائها في مياه الصرف أو مع اﻟﻤﺨلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تعد تستخدمها. سوف تُساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي: أمبول به 8.5 مل من المحلول الذي يحتوي على أسيتات تيرليبريسين بما يُعادِل 0.1 ملغم تيرليبريسين/ مل.</p><p>المكونات الأخرى هي: كلوريد الصوديوم، حمض الخليك ٩٩ ٪، أسيتات الصوديوم ثلاثي الهيدرات، ماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong>ما هو شكل عقار جليبريسين&nbsp;0.1 ملغم/ مل محلول للحقن وما هي محتويات العبوة</strong></p><p>عقار جليبريسين&nbsp;0.1 ملغم/ مل محلول للحقن عبارة عن محلول صاف عديم اللون.</p><p>يتوفر عقار جليبريسين&nbsp;0.1 ملغم/ مل محلول للحقن في عبوات بها 5 أمبولات بكل منها 8.5&nbsp;مل من المحلول.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>حامل حق التسويق</strong>: فيرينج جي ام بي اتش، ويتلند 11، د &ndash; 24109 كييل، ألمانيا.</p><p><strong>المصنع</strong>: زينتيفا كي. اس.، يو كابيلفوني&nbsp;130, 10237&nbsp;براغ،&nbsp;الجمهورية التشيكية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            كانون الثاني 2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                GLYPRESSIN® 1mg/8.5ml Solution for Injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active ingredient: 1 ampoule with 8.5 ml solution contains terlipressin acetate equivalent to 0.1 mg terlipressin/ml.
For full list of excipients see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection. Clear, colourless solution.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Bleeding oesophageal varices.</u><br />The administration of terlipressin is for emergency treatment in cases of acute bleeding from oesophageal varices until endoscopic therapy is available. Afterwards, administration of terlipressin for the treatment of bleeding from oesophageal varices is usually an adjuvant therapy to the endoscopic stopping of bleeding. Terlipressin can also be used for reducing early secondary bleeding.</p><p><br /><u>Hepatorenal syndrome</u><br />Emergency treatment of type 1 hepatorenal syndrome as defined by the ICA (international Club of Ascites) 2007 criteria, characterized by spontaneous acute renal insufficiency, in patients suffering from severe cirrhosis, with ascites.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u><br />Bleeding oesophageal varices.<br />Unless otherwise prescribed, initially 1-2 ampoules of GLYPRESSIN&reg; 1mg/8.5ml Solution for Injection (0.85 to 1.7 mg terlipressin) are administered intravenously in adults. The maintenance dose is 1 ampoule of GLYPRESSIN&reg; 1mg/8.5ml Solution for Injection after 4-6 hours. To adapt to the course of disease, the duration of treatment is to be reduced to 2-3 days.<br />The standard value for the maximum daily dose of GLYPRESSIN&reg; 1mg/8.5ml Solution for Injection is 6 x 17 &mu;g/kg body weight. For an adult person of 70 kg body weight, this corresponds to a dose of 8 to 9 ampoules (6.8-7.65 mg) per day, to be administered in 4-hour intervals.<br /><u>Hepatorenal syndrome</u><br />Terlipressin is usually started at a dose of 1 ampoule of GLYPRESSIN&reg; 1mg/8.5ml Solution for Injection (0.85 mg terlipressin) every 4 to 6 hours. The dose can be increased to a maximum of 2 ampoules of GLYPRESSIN&reg; 1mg/8.5ml Solution for Injection (1.7 mg terlipressin) every 4 hours if serum creatinine does not decrease at least 25 % after 3 days of treatment.<br />Treatment is maintained until serum creatinine has decreased below 1,5 mg/dl (133 &mu;mol/L). For patients with partial response (serum creatinine does not decrease &lt; 133 &mu;mol/L) or in those patients without reduction of serum creatinine, treatment should be discontinued within 14 days.<br />Recurrence after withdrawal of therapy is uncommon. Retreatment with terlipressin is generally<br />effective.<br />Clinical data indicates that adding human albumin 1g/kg body weight on the first day and afterwards in a dosage of 20 &ndash; 40 g/day may be more efficacious than treating with terlipressin alone in patients with hepatorenal syndrome. In most of the clinical studies examining the use of terlipressin for treatment of hepatorenal syndrome type 1, human albumin was administered simultaneously with these doses.<br />The standard average duration of treatment is 10 days. Maximum treatment duration should not exceed 14 days.</p><p>&nbsp;</p><p><br /><u>Method of administration:</u></p><p>GLYPRESSIN&reg; 1mg/8.5ml Solution for Injection is slowly administered intravenously.<br /><strong>Elderly patients:</strong>GLYPRESSIN&reg; 1mg/8.5ml Solution for Injection should be used with caution in patients over 70 years of age.<br /><strong>Paediatric population: </strong>GLYPRESSIN&reg; 1mg/8.5ml Solution for Injection is not recommended in children and adolescents due to insufficient experience on safety and efficacy.<br /><strong>Renal insufficiency:</strong>GLYPRESSIN&reg; 1mg/8.5ml Solution for Injection should only be used with caution in patients with chronic renal failure.<br /><strong>Hepatic insufficiency: </strong>A dose adjustment is not required in patients with liver failure.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - Hypersensitivity to the active ingredient or any of the other ingredients.
- Septic shock in patients with low cardiac output.
- Pregnancy.
- History of ischemic cardiovascular disease, since terlipressin may induce ischemia.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>GLYPRESSIN&reg; 1mg/8.5ml Solution for Injection should be used with caution and under close monitoring in case of the following concomitant diseases:<br />- Septic shock;<br />- Bronchial asthma;<br />- Respiratory deficiencies;<br />- Uncontrolled hypertension;<br />- Cerebral, coronary or peripheral vascular diseases (e.g. advanced arteriosclerosis);<br />- Pre-existing seizures (convulsions);<br />- Cardiac arrhythmias;<br />- Cardiac diseases;<br />- Coronary insufficiency or previous myocardial infarction;<br />- Chronic renal insufficiency,<br />- Elderly patients over 70 years of age as experience is limited in this group.</p><p><br />Hypovolaemic patients also often show increased vasoconstriction and atypical cardiac reactions.<br />Due to the low antidiuretic effect of terlipressin (only approx. 3 % of the antidiuretic action of native vasopressin), attention should be drawn to possible hyponatraemia and hypokalaemia, especially in patients with already disturbed electrolyte balance.<br />During treatment regular controls of blood pressure, ECG/EKG, heart rate, serum levels of sodium and potassium, as well as fluid balance are required.<br />GLYPRESSIN&reg; 1mg/8.5ml Solution for Injection is only to be used under continuous monitoring of the cardiovascular function using intensive medical units.<br />In case of emergency requiring immediate treatment before hospitalization, special attention is to be drawn to volume deficiency syndromes.<br />GLYPRESSIN&reg; 1mg/8.5ml Solution for Injection has no effect on arterial bleeding.<br />To avoid local necrosis at the injection site, an intravenous injection should be administered.</p><p><br /><em>Skin Necrosis:</em></p><p>During post-marketing experience several cases of cutaneous ischemia and necrosis unrelated to the injection site have been reported. Patients with peripheral venous hypertension or morbid obesity seem to have a greater tendency to this reaction. Therefore, extreme caution should be exercised when administering terlipressin in these patients.<br /><em>Torsade de pointes</em><strong>:</strong></p><p>During clinical trials and post-marketing experience, several cases of QT interval prolongation and ventricular arrhythmias including &quot;Torsade de pointes&quot; have been reported. In most cases, patients had predisposing factors such as basal prolongation of the QT interval, electrolyte abnormalities (hypokalemia, hypomagnesemia) or medications with concomitant effect on QT prolongation. Therefore, extreme caution should be exercised in the use of terlipressin in patients with a history of&nbsp;QT interval prolongation, electrolytic anormalities, concomitant medications that can prolong the QT interval, such as class IA and III antiarrhythmics, erythromycin, certain antihistamines and tricyclic antidepressants or medications that can cause hypokalaemia or hypomagnesemia (e.g. some diuretics).<br /><em>Special populations:</em><br /><u>Elderly</u>:There is only limited experience in the treatment of elderly; therefore, terlipressin should only be used in this population with special care. There are no dose recommendations for elderly.<br />Due to lack of data and experience, GLYPRESSIN&reg; 1mg/8.5ml Solution for Injection should not be used in children and adolescents.</p><p>8.5 ml of GLYPRESSIN&reg; 1mg/8.5ml Solution for Injection contain 1.34 mmol (30.71 mg) sodium. This should be considered in patients receiving sodium-controlled diet (low sodium/low salt).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Terlipressin increases the hypotensive effect of non-selective &beta;-blockers on the portal vein. The reduction in heart rate and cardiac output caused by the treatment can be attributed to the inhibition of the reflexogenic activity of the heart through the vagus nerve as a result of increased blood pressure. Concomitant treatment with drugs known to induce bradycardia (e.g. propofol, sufentanil) can cause severe bradycardia.<br />Terlipressin can trigger ventricular arrhythmias including &quot;Torsade de pointes&quot;. Therefore, extreme caution should be exercised in the use of terlipressin in patients with concomitant medications that can prolong the QT interval, such as class IA and III antiarrhythmics, erythromycin, certain antihistamines and tricyclic antidepressants or medications that may cause hypokalaemia or hypomagnesemia (e.g. some diuretics).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u><br />GLYPRESSIN&reg; 1mg/8.5ml Solution for Injection is contraindicated during pregnancy. GLYPRESSIN&reg; 1mg/8.5ml Solution for Injection causes uterine contractions and increased intrauterine pressure during early pregnancy and may reduce uterine blood flow.<br />GLYPRESSIN&reg; 1mg/8.5ml Solution for Injection may have a harmful effect on pregnancy and the health of the foetus. Rabbits showed spontaneous abortions and malformations following treatment with GLYPRESSIN&reg; 1mg/8.5ml Solution for Injection.<br /><u>Lactation</u>:&nbsp;</p><p>It is not known whether terlipressin passes into breast milk. The excretion of terlipressin in milk has not been studied in animals. A risk to the suckling child cannot be excluded. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with terlipressin should be made taking into account the benefit of breast-feeding to the child and the benefit of terlipressin therapy to the woman.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on ability to drive and use machines have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most commonly reported undesirable effects in clinical trials (frequency 1-10 %) are paleness, increased blood pressure, abdominal pain, nausea, diarrhoea and headache.<br />The antidiuretic effect of terlipressin may cause hyponatraemia unless the fluid balance is controlled.<br />The assessment of undesirable effects is based on the following grades of frequency:<br />Very common (&gt;=1/10)<br />Common (&gt;=1/100 to &lt;1/10)<br />Uncommon (&gt;=1/1,000 to &lt;1/100)<br />Rare (&gt;=1/10,000 to &lt;1/1,000)<br />Very rare (&lt;1/10,000)<br />Not known (frequency cannot be estimated from the available data)</p><p><strong>Metabolism and nutrition disorders:</strong><br /><u>Common (&gt;=1/100 to &lt;1/10)</u>: hyponatraemia<br /><strong>Nervous system disorders:</strong><br /><u>Common (&gt;=1/100 to &lt;1/10)</u> headache.<br /><u>Uncommon&nbsp;(&gt;=1/1,000 to &lt;1/100)</u>: causing of seizure disorders.<br /><u>Very rare&nbsp;(&lt;1/10,000)</u>: apoplexy<br /><strong>Cardiac disorders:</strong><br /><u>Common (&gt;=1/100 to &lt;1/10)</u>: bradycardia, ventricular and supraventricular arrhythmia, signs of ischaemia in ECG/EKG,<br /><u>Uncommon&nbsp;(&gt;=1/1,000 to &lt;1/100)</u>: acute hypertension rises in particular in patients already suffering from hypertension (generally, it decreases spontaneously), tachycardia, atrial fibrillation, ventricular extrasystoles, angina pectoris, myocardial infarction, overload of liquid with pulmonary oedema, torsade de pointes, cardiac insufficiency.<br /><u>Very rare&nbsp;(&lt;1/10,000)</u> myocardial ischemia<br /><strong>Vascular disorders:</strong><br /><u>Common (&gt;=1/100 to &lt;1/10)</u> peripheral vasoconstriction, peripheral ischaemia, hypertension, pallor of skin, hypo-tension<br /><u>Uncommon&nbsp;(&gt;=1/1,000 to &lt;1/100)</u>: intestinal ischaemia, peripheral cyanosis, hot flushes<br /><strong>Respiratory, thoracic and mediastinal disorders</strong>:<br /><u>Uncommon&nbsp;(&gt;=1/1,000 to &lt;1/100)</u>: difficulty in breathing, painful breathing, pain in the chest (thoracic pain), bronchial spasm, respiratory insufficiency, cessation of breathing,<br /><u>Rare (&gt;=1/10,000 to &lt;1/1,000)</u>: dyspnoea<br /><strong>Gastrointestinal disorders:</strong><br /><u>Common (&gt;=1/100 to &lt;1/10)</u>: spasmodic abdominal pain, nausea, diarrhoea.<br /><u>Uncommon&nbsp;(&gt;=1/1,000 to &lt;1/100)</u>: vomiting<br /><strong>Skin and subcutaneous tissue disorders:</strong><br /><u>Common (&gt;=1/100 to &lt;1/10)</u>: paleness.<br /><u>Uncommon&nbsp;(&gt;=1/1,000 to &lt;1/100)</u>: lymphangitis, skin necrosis<br /><strong>Pregnancy, puerperium and perinatal conditions:</strong><br /><u>Uncommon&nbsp;(&gt;=1/1,000 to &lt;1/100)</u>: Uterine hypertonus, Uterine ischemia<br /><strong>General disorders and administration site conditions:</strong><br /><u>Uncommon&nbsp;(&gt;=1/1,000 to &lt;1/100)</u>: necrosis at injection site<br /><strong>Reproductive system and breast disorders:</strong><br /><u>Common (&gt;=1/100 to &lt;1/10)</u>: spasmodic pain in the lower abdomen (in women)During post-marketing experience, several cases of QT interval prolongation and ventricular arrhythmias including &quot;Torsade de pointes&quot; have been reported and several cases of cutaneous ischemia and necrosis unrelated to the injection site have been reported.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The recommended dose (1.7 mg/4 hours) should not be exceeded as the risk of severe circulatory disorders increases with the dose. Increased blood pressure in patients with known hypertension can be controlled with 150 &mu;g clonidine IV. Bradycardia requiring therapy should be treated with atropine.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: systemic hormonal preparations, posterior pituitary hormones, vasopressin and analogues<br />ATC code: H01BA04<br />Terlipressin possesses little pharmacological activity, however, it is metabolized into the active lysine vasopressin by enzymatic hydrolysis. Doses of 0.85 mg and 1.7 mg lower the portal pressure and cause marked vasoconstriction. The lowering of the portal pressure and the reduction in the blood flow of the azygous vein are dose-dependent. The effect of the lower dose decreased after 3 hours, while haemodynamic data show that terlipressin 1.7 mg is more effective than 0.85 mg as the higher dose has a more reliable effect over the entire period of treatment (4 hours).</p><p><br />Terlipressin reduces the portal hypertension, simultaneously reducing the circulation in the portal vascular zone and contracting the unstriated oesophageal muscles under consecutive compression of the oesophageal varices.</p><p><br />The bioactive lysine vasopressin (LVP) is released protracted from the inactive hormonogen terlipressin and remains in a concentration range above the minimum effective and below the toxic concentration over a period of 4 - 6 hours due to the metabolic elimination of the LVP that is in parallel to the release. The specific actions of terlipressin are to be evaluated as follows:<br /><u>Gastrointestinal system:</u></p><p>Terlipressin increases the tonus of vasal and extravasal unstriated muscle cells. Due to the increased resistance of the terminal arterial vessels, there is a decreased circulation of the splanchnic nerve. Reduction of the arterial flow leads to a pressure decrease in the portal circulation. The simultaneous contraction of the intestinal muscles leads to an increased peristalsis. Furthermore, it could be shown that the muscles of the oesophageal wall are contracting and thus &ldquo;ligate&rdquo; varices experimentally created.</p><p><u>Kidney:</u></p><p>Terlipressin has only 3 % of the antidiuretic action of native vasopressin. This reactivity is not clinically relevant. Renal circulation is not significantly changed in normovolaemic condition. In hypovolaemic condition, renal circulation is increased.</p><p><u>Blood pressure:</u></p><p>The use of terlipressin has a slow haemodynamic effect over 2 - 4 hours. The blood pressure is slightly increased systolically and diastolically. In case of renal hypertonia and general vascular sclerosis, stronger blood pressure increases were observed.</p><p><u>Heart: </u></p><p>No cardiotoxic effects, even with the highest dosage, have been determined under terlipressin. Influences on the heart, such as bradycardia, arrhythmia, coronary insufficiency, occur possibly because of reflex or direct vascular constrictive effects of terlipressin.</p><p><u>Uterus:</u></p><p>Under terlipressin, blood circulation of the myometrium and endometrium is strongly decreased.</p><p><u>Skin:</u></p><p>Due to its vasoconstricting effect, terlipressin leads to an insufficient blood circulation of the skin. All authors report a clearly visible paleness of body and skin in their patients.</p><p>The haemodynamic effect and the effect on the unstriated muscle cells are the main factors in the pharmacology of terlipressin. The centralizing effect in hypovolaemic condition is a desired side effect in patients with bleeding oesophageal varices.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The mean plasma half-life of terlipressin is 24 + 2 minutes. After an IV bolus injection, terlipressin is eliminated according to a 2nd order kinetics. For the distribution phase (up to 40 minutes), a plasma half-life of 12 minutes has been determined. By setting free singular rest-glycyl, the hormone lysine-vasopressine is slowly released and reaches its peak concentration after 120 minutes. Only 1 % of the injected terlipressin can be detected in the urine. This indicates a nearly complete degradation by endo- and exo-peptidases of the liver and the kidney.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no hazard for humans based on conventional studies of single-and multiple dose toxicity as well as genotoxicity. No carcinogenicity studies have been performed with terlipressin. At doses relevant to humans, the only effects observed in animals were those attributed to the pharmacological activity of terlipressin. There are no pharmacokinetic data from animal models available which would allow comparison with human plasma concentrations. However, as administration is done by the intravenous route, substantial systemic exposition can be assumed.<br />An embryo-foetal study in rats showed no side effects of terlipressin. In rabbits, however,<br />abortions occurred that were probably related to maternal toxicity. Furthermore, a small<br />number of foetuses showed ossification anomalies and a single case of cleft palate was observed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium chloride, acetic acid 99 %, sodium acetate 3 H2O, water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Incompatibilities are unknown at present.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Look at the outer carton
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in refrigerator (2 &deg;C &ndash; 8 &deg;C). Keep ampoules in the outer carton, in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Colorless glass ampoule.<br />Pack size: OP with 5 ampoules with 8.5 ml solution each</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with national requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ferring GmbH, Wittland 11, D-24109,
Kiel, Germany.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                January 2019.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>